RPP # | Requirement Topic | Description | Requiring Office | Submission Due Date |
---|---|---|---|---|
RPP-24-06-DxR2 (3/27/2024) | Biothreat Diagnostic Rapid Response | Through this Request for Project Proposals (RPP) BARDA is seeking to address its product portfolio capability readiness gaps for rapid biothreat diagnostic test development and ready-production capacity to quickly produce tests in lieu of stockpiling. Biothreat tests will be developed and pilot program(s) will be established to assess the feasibility of rapid response capabilities, leveraging existing domestic manufacturing capacities. | 5/17/2024 1pm Eastern | |
Q3FY24 RPP | Project NextGen: On Demand Manufacturing | Slides from the On Demand Manufacturing Virtual Industry Day (1/16/2024) Available Here | ||
Q3-Q4FY24 | mRNA Vaccine Platform Production Capability for Rapid Pandemic and Priority Threat Response | The requirements for mRNA Vaccine Platform Production Capability for Rapid Pandemic and Priority Threat Response are being redefined. As we redefine the requirements, we will actively communicate updates. | IEID | TBD |
RPP # (Date) | Requirement Topic | Closed Date |
---|---|---|
RPP-24-03-Treatment (02/21/2024) | Project NextGen: Therapeutics | 5/13/2024 |
RPP-24-05-NGClinMfg (01/16/2024) | Project NextGen: Innovation in Clinical Manufacturing of COVID-19 Vaccines | 04/19/2024 |
RPP-24-04-NGVxStats (2/23/2024) | NextGen Vaccines: Statistical Support, Correlates of Protection, and Meta-analysis | 03/27/2024 |
RPP-24-04-NGVxAssays (2/15/2024) | NextGen Vaccines: Immune Assays | 3/22/2024 1pm Eastern |
RPP-24-02-Retail (2/2/2024) | Enabling Technology – Decentralized Clinical Trial – Retail/Pharmacy Focus | 03/20/2024 |
RPP-24-03-PrEP (11/30/2023) | COVID-19 Monoclonal Antibody Therapeutics for PrEP | 01/19/2024 |
RPP-24-02-HomeFocus (11/30/2023) | Enabling Technology – Decentralized Clinical Trial – Home Focus | 01/19/2024 |
RPP-24-04-NGVx (11/30/2023) | NextGen Vaccinations: Phase 2B Clinical Trial Execution | 01/10/2024 |
RPP-24-01-mRNA | Accelerating Near-Term Availability of mRNA-based Pandemic Influenza Vaccine | 12/4/2023 |